Cem Meydan

Cem Meydan

Auto-generated profile, based on publicly available information

Cem Meydan

Department of Physiology and Biophysics, Weill Cornell Medicine, New York, NY, USA

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2015 in Nature Methods
Verified
Journal Article
Open access
PDF file
BLBastian Linder
Bastian Linder
AGAnya V Grozhik
Anya V Grozhik
AOAnthony O Olarerin-George
Anthony O Olarerin-George
CMCem Meydan
Cem Meydan
CMChristopher E Mason
Christopher E Mason
SJSamie Jaffrey
Samie Jaffrey
Unique mutational signatures induced by cross-linking of m6A-specific antibodies to RNA identify m6A and m6Am residues at single-nucleotide resolution, transcriptome-wide. N6-methyladenosine (m6A) is the most abundant modified base in eukaryotic mRNA and has been linked to diverse effects on mRNA fate. Current mapping approaches localize m6A residues to transcript regions 100–200 nt long but cannot identify precise m6A positions on a transcriptome-wide level. Here we developed m6A individual-nucleotide-resolution cross-linking and immunoprecipitation (miCLIP) and used it to demonstrate that antibodies to m6A can induce specific mutational signatures at m6A residues after ultraviolet light–induced antibody-RNA cross-linking and reverse transcription. We found that these antibodies similarly induced mutational signatures at N6,2′-O-dimethyladenosine (m6Am), a modification found at the first nucleotide of certain mRNAs. Using these signatures, we mapped m6A and m6Am at single-nucleotide resolution in human and mouse mRNA and identified small nucleolar RNAs (snoRNAs) as a new class of m6A-containing non-coding RNAs (ncRNAs).

12 April 2019 in Science
Verified
Journal Article
Closed access
PDF file
FGFrancine E. Garrett-Bakelman
Francine E. Garrett-Bakelman
MDManjula Darshi
Manjula Darshi
SGStefan J. Green
Stefan J. Green
RGRuben C. Gur
Ruben C. Gur
LLLing Lin
Ling Lin
FTFred Turek
Fred Turek
What to expect after a year in space: Space is the final frontier for understanding how extreme environments affect human physiology. Following twin astronauts, one of which spent a year-long mission on the International Space Station, Garrett-Bakelman et al. examined molecular and physiological traits that may be affected by time in space (see the Perspective by Löbrich and Jeggo). Sequencing the components of whole blood revealed that the length of telomeres, which is important to maintain in dividing cells and may be related to human aging, changed substantially during space flight and again upon return to Earth. Coupled with changes in DNA methylation in immune cells and cardiovascular and cognitive effects, this study provides a basis to assess the hazards of long-term space habitation. Science , this issue p. eaau8650 ; see also p. 127

1 November 2020 in Cell
Verified
Journal Article
Closed access
EAEbrahim Afshinnekoo
Ebrahim Afshinnekoo
RSRyan T. Scott
Ryan T. Scott
MMMatthew J. MacKay
Matthew J. MacKay
EPEloise Pariset
Eloise Pariset
ECEgle Cekanaviciute
Egle Cekanaviciute
ABAfshin Beheshti
Afshin Beheshti

29 March 2021 in Nature
Verified
Journal Article
Closed access
PDF file
ARAndré F. Rendeiro
André F. Rendeiro
HRHiranmayi Ravichandran
Hiranmayi Ravichandran
YBYaron Bram
Yaron Bram
VCVasuretha Chandar
Vasuretha Chandar
JKJunbum Kim
Junbum Kim
RSRobert E. Schwartz
Robert E. Schwartz

1 July 2015 in Cell Systems
Verified
Journal Article
Open access
EAEbrahim Afshinnekoo
Ebrahim Afshinnekoo
CMCem Meydan
Cem Meydan
SCShanin Chowdhury
Shanin Chowdhury
DJDyala Jaroudi
Dyala Jaroudi
CBCollin Boyer
Collin Boyer
Christopher MasonChristopher Mason
Christopher Mason
The panoply of microorganisms and other species present in our environment influence human health and disease, especially in cities, but have not been profiled with metagenomics at a city-wide scale. We sequenced DNA from surfaces across the entire New York City (NYC) subway system, the Gowanus Canal, and public parks. Nearly half of the DNA (48%) does not match any known organism; identified organisms spanned 1,688 bacterial, viral, archaeal, and eukaryotic taxa, which were enriched for harmless genera associated with skin (e.g., Acinetobacter). Predicted ancestry of human DNA left on subway surfaces can recapitulate U.S. Census demographic data, and bacterial signatures can reveal a station’s history, such as marine-associated bacteria in a hurricane-flooded station. Some evidence of pathogens was found (Bacillus anthracis), but a lack of reported cases in NYC suggests that the pathogens represent a normal, urban microbiome. This baseline metagenomic map of NYC could help long-term disease surveillance, bioterrorism threat mitigation, and health management in the built environment of cities.

1 January 2017 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
YJYanwen Jiang
Yanwen Jiang
AOAna Ortega-Molina
Ana Ortega-Molina
HGHuimin Geng
Huimin Geng
HYHsia-Yuan Ying
Hsia-Yuan Ying
KHKaterina Hatzi
Katerina Hatzi
AMAri M. Melnick
Ari M. Melnick
Somatic mutations in CREBBP occur frequently in B-cell lymphoma. Here, we show that loss of CREBBP facilitates the development of germinal center (GC)–derived lymphomas in mice. In both human and murine lymphomas, CREBBP loss-of-function resulted in focal depletion of enhancer H3K27 acetylation and aberrant transcriptional silencing of genes that regulate B-cell signaling and immune responses, including class II MHC. Mechanistically, CREBBP-regulated enhancers are counter-regulated by the BCL6 transcriptional repressor in a complex with SMRT and HDAC3, which we found to bind extensively to MHC class II loci. HDAC3 loss-of-function rescued repression of these enhancers and corresponding genes, including MHC class II, and more profoundly suppressed CREBBP-mutant lymphomas in vitro and in vivo. Hence, CREBBP loss-of-function contributes to lymphomagenesis by enabling unopposed suppression of enhancers by BCL6/SMRT/HDAC3 complexes, suggesting HDAC3-targeted therapy as a precision approach for CREBBP-mutant lymphomas. Significance: Our findings establish the tumor suppressor function of CREBBP in GC lymphomas in which CREBBP mutations disable acetylation and result in unopposed deacetylation by BCL6/SMRT/HDAC3 complexes at enhancers of B-cell signaling and immune response genes. Hence, inhibition of HDAC3 can restore the enhancer histone acetylation and may serve as a targeted therapy for CREBBP-mutant lymphomas. Cancer Discov; 7(1); 38–53. ©2016 AACR. See related commentary by Höpken, p. 14. This article is highlighted in the In This Issue feature, p. 1